Abstract 6042
Background
Leadership is nursing is widely discussed and recognised as an important element in nursing services and indeed in health service development. Nurse leaders are in a prime position to facilitate and drive change within the healthcare setting. Nurse leaders can be role models within the workforce and integral in guiding and motivating teams to meet organisational goals. Whilst it often feels change within the clinical environment, occurs at a rapid rate or too frequently, resulting in a degree of change fatigue amongst nursing colleagues. Organisational change is often in response to advancements in medical knowledge, workforce demands or in this case, infrastructure change in response to increased demand upon a service. The authors work in a busy cancer centre, which delivers day case chemotherapy to approximately 130 patients a day. Delays resulting from patients attending day care in blocks of time resulted in bottle necks, meaning many faced long waits for their chemotherapy. A new scheduling system was implemented to focus booking patients based on chair availability and thus staggered more consistently across the day. The objective of the change was to improve patients’ attendance on our chemotherapy day unit, to prevent lengthy delays and streamline the process of delivering chemotherapy. The focus of this review, is how nursing leadership was instrumental in delivering change and how nurses are optimally positioned to drive change and manage projects in the healthcare setting.
Methods
A project was undertaken to implement a new electronic system for scheduling chemotherapy for a busy chemo day service. The project was led by oncology nurses within the service.
Results
The project outcome to implement a new electronic scheduling system was achieved in a timely manner. The project drivers did encounter some reticence, when colleagues faced new ways of working. Open and constant dialogue was maintained to ensure all stakeholders were fully apprised of the rationale for the change, the timescale and outcomes.
Conclusions
The importance of steady, intelligent leadership from nurses cannot be overestimated. Solidarity amongst nursing colleagues and allied health professionals is essential to optimise organisational efficacy and quality of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract